Breaking News Instant updates and real-time market news.

KMB

Kimberly-Clark

, UN

Unilever; also tag UL

09:41
02/17/17
02/17
09:41
02/17/17
09:41

Unusually active option classes on open February 17th

Unusual total active option classes on open include: Kimberly Clark (KMB), Unilever (UN), Deere (DE), Weatherford (WFT), AstraZeneca (AZN), UnitedHealth (UNH), S&P 500 PM Settled Index (.SPXPM), Texas Instruments (TXN), Mondelez (MDLZ), and Tesla (TSLA).

KMB

Kimberly-Clark

UN

Unilever; also tag UL

DE

Deere

WFT

Weatherford

AZN

AstraZeneca

UNH

UnitedHealth

TXN

Texas Instruments

$76.25

0.58 (0.77%)

MDLZ

Mondelez

$43.20

-2.17 (-4.78%)

TSLA

Tesla

$268.95

-10.81 (-3.86%)

  • 17

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Mar

  • 17

    Mar

  • 19

    Mar

  • 01

    Apr

  • 26

    Jun

KMB Kimberly-Clark

10/26/16
10/26/16
DOWNGRADE

Underperform
Kimberly-Clark downgraded to Underperform on emerging market weakness at CLSA
As previously reported, CLSA downgraded Kimberly-Clark to Underperform from Outperform and lowered its price target to $116 from $131. Analyst Caroline Levy believes pricing weakness in China will continue as P&G, Kao, and Unicharm, and local competitors compete for share. In the US, she expects P&G to remain aggressive in adult diaper promotions, a key category for Kimberly and said Brazil and Argentina have just begun to weaken. Levy's 2017 and 2018 estimates are below the Street and said a slight contraction in multiple is likely.
11/14/16
WELS
11/14/16
INITIATION
WELS
Market Perform
Kimberly-Clark coverage resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Bonnie Herzog resumed coverage on Kimberly-Clark with a Market Perform and a $117-$119 valuation range.
01/09/17
LEHM
01/09/17
DOWNGRADE
Target $109
LEHM
Equal Weight
Kimberly-Clark downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Lauren Lieberman downgraded Kimberly-Clark to Equal Weight after lowering her U.S. Non-Food Consumer Staples sector view to Neutral from Positive. The analyst lowered her price target for the shares to $109 from $125. The analyst sees a less favorable macroeconomic backdrop in 2017 and has "fairly muted expectations" for company fundamentals in the space.
10/26/16
LYON
10/26/16
DOWNGRADE
LYON
Underperform
Kimberly-Clark downgraded to Underperform from Outperform at CLSA
UN Unilever; also tag UL

01/23/17
01/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jennifer Fritzsche saying the stock's outperformance since U.S. presidential election is not sustainable given growth headwinds in 2017. 2. Qualcomm (QCOM) downgraded to Neutral from Buy at Nomura and to Underperform from Buy at CLSA. 3. Schlumberger (SLB) downgraded to Equal Weight from Overweight at Stephens with analyst Matthew Marietta saying he remains confident in Schlumberger's ability to benefit from the Cameron (CAM) integration, and its wide-ranging suite of products/services. 4. Unilever (UL, UN) downgraded to Equal Weight from Overweight at Barclays with analyst Simon Hales citing recent sector outperformance, currency uncertainty, and rising oil related input costs. 5. Kansas City Southern (KSU) downgraded to Neutral from Accumulate at Seaport Global with analyst Mark Levin saying there is too much uncertainty around U.S./Mexico trade policy to accurately forecast what earnings will look like in 2019 and beyond. The analyst acknowledges shares are "cheap" and maintained his $90 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/17
LEHM
01/23/17
DOWNGRADE
LEHM
Equal Weight
Unilever downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Simon Hales downgraded Unilever to Equal Weight citing recent sector outperformance, currency uncertainty, and rising oil related input costs.
12/06/16
JPMS
12/06/16
DOWNGRADE
JPMS
Neutral
Unilever downgraded to Neutral from Overweight at JPMorgan
12/13/16
JEFF
12/13/16
UPGRADE
JEFF
Buy
Unilever upgraded to Buy from Hold at Jefferies
Jefferies analyst Martin Deboo upgraded Unilever to Buy and raised his price target for the shares to EUR 44 from EUR 40.
DE Deere

01/18/17
OTRG
01/18/17
NO CHANGE
OTRG
North American Farm Equipment sector upgraded to Mixed at OTR Global
OTR Global upgraded the North American Farm Equipment sector to Mixed following positive dealer checks that indicates farm income is better than expected. The firm's analyst now expects 2017 sales to be down 1-4% year-over-year, versus October forecast of down 3-6%.
01/24/17
BREN
01/24/17
INITIATION
Target $90
BREN
Sell
Deere initiated with a Sell at Berenberg
Berenberg analyst Sabastian Juenne initiated Deere with a Sell and a $90 price target. The analyst's 2017 earnings estimate is in-line with consensus but his 2018 earnings forecast is approximately 18% below as he does not expect a meaningful recovery in agricultural equipment spending in North America and Europe in 2018. Juenna said Deere's high exposure to struggling North American and low exposure to resilient markets, could result in a subdued earnings recovery versus more diversified peers.
02/10/17
CLVD
02/10/17
NO CHANGE
CLVD
Deere survey indicates a significant improvement in demand, says Cleveland
Cleveland Research analyst Adam Uhlman said the firm's North American ag equipment dealer survey saw a significant increase in demand with 70% of dealers reporting better than expected Q1 sales. Dealers raised their 2017 sales forecast to down 1% year-over-year from down 8% last quarter, with sentiment largely better. Uhlman raised his FY17 earnings forecast to $5.00 from $4.55 and FY18 to $5.50 from $5.00. The analyst rates Deere a Neutral.
01/24/17
01/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Deere (DE) initiated with a Sell at Berenberg, while the firm initiated AGCO (AGCO) with a Buy. 2. Douglas Dynamics (PLOW) initiated with a Buy at Craig-Hallum. 3. DCP Midstream (DCP) initiated with an Underweight at Morgan Stanley. 4. TechnipFMC (FTI) initiated with a Buy at Goldman. 5. FS Investment (FSIC) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WFT Weatherford

01/27/17
JEFF
01/27/17
DOWNGRADE
Target $6
JEFF
Hold
Weatherford downgraded to Hold from Buy at Jefferies
Jefferies analyst Brad Handler downgraded Weatherford to Hold citing a challenging international landscape, "disappointing" free cash flow in 2016 and continued share dilution. The analyst lowered his price target for the shares to $6 from $7.
02/03/17
LOOP
02/03/17
UPGRADE
Target $8
LOOP
Buy
Weatherford upgraded to Buy from Hold at Loop Capital
Loop Capital analyst Stephen Gengaro upgraded Weatherford International to Buy saying CEO Krishna Shirvam's strategy to restore profitability is "reasonable, logical and achievable." The analyst raised his price target for the shares to $8 from $7.
02/03/17
UBSW
02/03/17
NO CHANGE
Target $9
UBSW
Buy
Weatherford game plan to strengthen company viewed positively at UBS
UBS analyst Angie Sedita said the game plan to strengthen both the company finances and operations at Weatherford are being viewed positively. She did say the free cash flow will be critical to the plans and the company remains a classic risk/return story. The increased visibility gives her a higher degree of confidence than the prior vague commentary. Sedita reiterated her Buy rating and $9 price target on Weatherford shares.
01/27/17
01/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Whirlpool (WHR) downgraded to Neutral from Buy at Goldman with analyst Samuel Eisner saying "tough" pricing in North America and "stronger" raw material headwinds should limit margin expansion. The analyst sees some risk to Whirlpool's 2017 guidance, especially in the back half of the year, and cut his price target for the shares to $187 from $191. 2. JetBlue (JBLU) was downgraded to Hold from Buy at Argus and to Underperform from Peer Perform at Wolfe Research. 3. Weatherford (WFT) downgraded to Hold from Buy at Jefferies with analyst Brad Handler citing a challenging international landscape, "disappointing" free cash flow in 2016 and continued share dilution. The analyst lowered his price target for the shares to $6 from $7. 4. Graphic Packaging (GPK) downgraded to Buy from Conviction Buy at Goldman with analyst Brian Maguire saying shares have underperformed since the guidance cut in October due to weaker end markets, higher OCC costs, foreign exchange, inventory restocking, Hurricane Mathew, and inventory restocking. 5. 8point3 Energy (CAFD) was downgraded to Underperform from Market Perform at Avondale and to Neutral from Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca

01/30/17
SBSH
01/30/17
NO CHANGE
Target $151
SBSH
Buy
TESARO could be worth up to $238/share in a takeover, says Citi
Citi analyst Robyn Karnauskas estimates that TESARO (TSRO) could be valued at $208-$238 per share in a deal to be acquired. The stock closed Friday up 49c to $153.85. Multiple catalysts in TESARO's immune-oncology program throughout 2017 could cause investors to gain confidence and assign value to the program, Karnauskas tells investors in a research note. She keeps a Buy rating on the shares with a $151 price target. The analyst says she's been getting questions around the competitive landscape in the PARP space and potential M&A valuations ahead of the SOLO-2 data from AstraZeneca (AZN) expected in Q1.
01/12/17
PIPR
01/12/17
UPGRADE
Target $72
PIPR
Overweight
Merck upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss upgraded Merck (MRK) to Overweight saying he expects the FDA will conditionally approve the use of Keytruda plus chemo by May 10. Keytruda's adoption in first-line lung cancer would then be "substantially brought forward" to the initial detriment of Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY), Purkiss tells investors in a research note. The earlier than expected boost to Keytruda sales increases the analyst's 2017-2019 earnings forecasts for Merck by 12%-18%. Purkiss raised his price target for the shares to $72 from $63. The stock closed yesterday up $1.71 to $61.63.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Outperform
Clovis Rubraca approval unlikely to impact TESARO niraparib, says Leerink
Commenting on Clovis' (CLVS) Rubraca accelerated approval by the FDA for the treatment of germline or somatic BRCA-mutated ovarian cancer patients, Leerink analyst Seamus Fernandez says the label appears "fairly broad" and does not restrict use based on platinum sensitivity/resistance. While he believes this current approval is unlikely to impact the initial competitive dynamics for TESARO's (TSRO) niraparib or AstraZeneca's (AZN) Lynparza in second-line maintenance, the analyst points out that data from Rubraca's Phase 3 ARIEL3 trial in this setting is now expected in mid-2017. Despite the earlier readout, Fernandez continues to see niraparib as the ultimate winner in second-line maintenance. He reiterates an Outperform rating on TESARO's shares.
02/17/17
WBLR
02/17/17
NO CHANGE
WBLR
Outperform
William Blair estimates $102/share buyout value for SAGE
After SAGE Therapeutics (SAGE) CEO Jeff Jonas noted during an interview yesterday that his company has received takeover interest, William Blair analyst Tim Lugo made some estimates on what SAGE could garner in a takeout scenario. An acquisition is unlikely before the Phase III studies set to report out through midyear as well as several other proof-of-concept studies, Lugo cautions. He believes, however, that the company's "strong pipeline of central nervous system targeting therapies" would be complementary to a number of larger companies, including Allergan (AGN), AstraZeneca (AZN) and potentially Biogen (BIIB). When using comparable acquisitions of companies in the pre-commercial phase with a median premium of 55% to the prior close and a 2.8 times enterprise value to his peak sales estimate of $1.5B, Lugo arrives at potential takeover value for SAGE of $102 per share, or a $4.2B enterprise value. Using a sum-of-the-parts analysis, the analyst arrives at a fair-value estimate between $95 and $100 per share. SAGE in early trading is down $2.36 to $60.39. Lugo has an Outperform rating on the stock.
UNH UnitedHealth

02/06/17
CANT
02/06/17
INITIATION
Target $200
CANT
Overweight
UnitedHealth initiated with an Overweight at Cantor
Cantor analyst Steven Halper initiated UnitedHealth with an Overweight and a $200 price target.
02/17/17
WELS
02/17/17
NO CHANGE
WELS
Outperform
UnitedHealth could face larger fines with DOJ involved, says Wells Fargo
Wells Fargo analyst Peter Costa notes that a whistle blower lawsuit against UnitedHealth focusing on Medicare Advantage and the way members are coded for risk has been unsealed and that the Justice Department has joined some of the claims. The presence of the Justice Department could result in a larger fines and damages than the typical risk score resolutions, Costa tells investors in a research note. A false claims act lawsuit carries potential treble damage penalties, the analyst points out. Costa adds that UnitedHealth stated it will contend the claims vigorously and that the company believes it has complied with the program's rules. The analyst has an Outperform rating on UnitedHealth. The stock is down 3% to $158.01 in pre-market trading.
02/07/17
02/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Target (TGT) and Dollar General (DG) were initiated with an Outperform at Bernstein, while Lowe's (LOW) was initiated with an Underperform. The firm also initiated Costco (COST), Home Depot (HD), and Wal-Mart (WMT) with a Market Perform. 2. Aetna (AET) and UnitedHealth (UNH) were assumed with an Overweight at Cantor. 3. Philips (PHG) initiated with a Hold at Berenberg. 4. Costamare (CMRE) initiated with a Neutral at Citi. 5. BioMarin (BMRN) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/17
CANT
02/07/17
NO CHANGE
Target $200
CANT
UnitedHealth transferred with a Buy at Cantor
Cantor Fitzgerald analyst Steven Halper assumed coverage of UnitedHealth with a Buy rating and $200 price target.
TXN Texas Instruments
$76.25

0.58 (0.77%)

02/10/17
SBSH
02/10/17
NO CHANGE
SBSH
Neutral
Citi says Intel should be like Texas Instruments, not Amazon
After Intel (INTC) at yesterday's analyst day lowered its margin targets due to higher spending and growth from low-margin markets, Citi analyst Christopher Danely says the company is trying to be like Amazon.com (AMZN) but should be more like Texas Instruments (TXN). Intel's multiple will suffer if margins decline, Danely tells investors in a research note. He continues to believe the stock would benefit if Intel exited lower-margin growth markets such as wireless and memory. The analyst keeps a Neutral rating on the name.
02/01/17
02/01/17
NO CHANGE

Pacific Crest identifies chip names with positive read throughs from Apple
Pacific Crest says that the following semiconductor companies have "modest" positive read throughs from Apple's (AAPL) results: Analog Devices (ADI), Broadcom (AVGO), Cirrus Logic (CRUS), ON Semiconductor (ON), Qualcomm (QCOM), Qorvo (QRVO), Skyworks(SWKS), Synaptics (SYNA), TSMC (TSM) and Texas Instruments (TXN). The firm identifies Broadcom as its favorite name in the group and recommends buying the stock.
01/25/17
OPCO
01/25/17
NO CHANGE
Target $90
OPCO
Outperform
Texas Instruments price target raised to $90 from $80 at Oppenheimer
Oppenheimer analyst Rick Schafer raised his price target for Texas Instruments to $90 from $80 after the company reported its latest round of beat/raise results. The analyst remains a long-term buyer and reiterates an Outperform rating on the shares.
01/25/17
UBSW
01/25/17
NO CHANGE
Target $85
UBSW
Buy
Texas Instruments price target raised to $85 from $80 at UBS
UBS Stephen Chin raised his price target on Texas Instruments to $85 from $80 following Q4 results that he called solid. The analyst noted its solid execution with growth in the automotive and industrial segments and sees more gross margin improvement over the next few years. Chin reiterated his Buy rating on Texas Instruments shares.
MDLZ Mondelez
$43.20

-2.17 (-4.78%)

02/15/17
02/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kraft Heinz (KHC) and ConAgra Brands (CAG) were initiated with Buy ratings at Deutsche Bank. The firm also initiated Campbell Soup (CPB), J.M. Smucker (SJM) General Mills (GIS), Hershey (HSY), Kellogg (K) and Mondelez (MDLZ) with a Hold, as well as Pinnacle Foods (PF), Hostess Brands (TWNK) and Snyder's Lance (LNCE) with a Buy. 2. MasterCard (MA) and Visa (V) initiated with Buy ratings at Loop Capital by analyst Joseph Vafi. 3. Bioverativ (BIVV) initiated with an Outperform rating and $56 price target at Leerink by analyst Jason Gerberry. 4. Encana (ECA) initiated with an Overweight at JPMorgan. The firm also reinstated Cheniere Energy (LNG) and Cheniere Energy Partners LP (CQH) with Overweight ratings. 5. Blueprint Medicines (BPMC) initiated with an Overweight at Morgan Stanley by analyst Andrew Berens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
02/15/17
DBAB
02/15/17
INITIATION
Target $49
DBAB
Hold
Mondelez initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Rob Dickerson started Mondelez with a Hold rating and $49 price target.
02/08/17
02/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying the company's Hepatitis C virus guidance of $7.5B-$9B is considerably lower than consensus at $12B and her estimate of $10B. The shares, around $69-$70, do not leave enough upside to justify a Buy recommendation, Karnauskas tells investors in a post-earnings research note. She believes the new guidance could create a new floor in the stock and cut her price target for Gilead to $76 from $87. 2. Mondelez (MDLZ) downgraded to Neutral from Positive at Susquehanna with analyst Pablo Zuanic citing its longer lasting challenges, including foreign exchange, macro, competitive issues and political uncertainty. Other reasons cited for the downgrade include the lower probability of an M&A bid, its premium valuation, and its falling gross margins. Zuanic lowered his price target to 446 from $53 on Mondelez shares. 3. Mosaic (MOS) downgraded to Outperform from Buy at CLSA with analyst Mark Connelly citing valuation. 4. Netgear (NTGR) downgraded to Market Perform from Outperform at Raymond James with analyst Tavis McCourt saying shares have surpassed his previous $55 price target and results and guidance do not provide a catalyst to raise the target. 5. CoreSite Realty (COR) downgraded to Neutral from Buy at Guggenheim with analyst Jonathan Schildkraut citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/17
SUSQ
02/08/17
DOWNGRADE
Target $46
SUSQ
Neutral
Mondelez downgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Pablo Zuanic downgraded Mondelez to Neutral from Positive citing its longer lasting challenges, including foreign exchange, macro, competitive issues and political uncertainty. Other reasons cited for the downgrade include the lower probability of an M&A bid, its premium valuation, and its falling gross margins. Zuanic lowered his price target to 446 from $53 on Mondelez shares.
TSLA Tesla
$268.95

-10.81 (-3.86%)

02/09/17
BARD
02/09/17
NO CHANGE
Target $338
BARD
Outperform
Tesla should be bought ahead of Q4 results, says Baird
Baird analyst Ben Kallo said he is a buyer of Tesla shares ahead of Q4 results, which he believes will be another de-risking event for the company. Although he said there could be short-term noise as expectations are calibrated, he recommends owning the shares. He expects an update on the Model 3 and Gigafactory production ramps, which he believes will drive the shares higher. Kallo reiterated his Outperform rating and $338 price target on Tesla shares.
02/15/17
COWN
02/15/17
NO CHANGE
Target $155
COWN
Underperform
Tesla estimates lowered ahead of Q4 results at Cowen
Cowen analyst Jeffrey Osborne lowered his Q4 estimates, but raised his Q1 estimates, on Tesla ahead of results. The analyst cited the timing of revenue recognition for autopilot release. He noted the results will include SolarCity for the first time and he will be looking for unit guidance, an update on Model 3 reservations, its Gigafactory ramp, as well as general capital needs for 2017. Osborne reiterated his Underperform rating and $155 price target on Tesla shares.
01/19/17
01/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas citing an increased Model 3 volume estimate and accelerated launch timeline, as he now assume a "soft" launch of the mass-market model in the fourth quarter of this year and bumped up his fiscal 2018 volume estimate to 183,000 units from 114,000. Jonas also argues that the recent pullback in tech company efforts to make complete vehicles reduces Tesla's potential competition and he believes the political environment and industry trends are supportive of Tesla. The analyst raises increased his price target on the shares to $305 from $242. 2. Netflix (NFLX) upgraded to Neutral from Underperform at Macquarie with analyst Tim Nollen citing the company's fourth quarter earnings beat and solid first quarter guidance. 3 Verizon (VZ) upgraded to Buy from Hold at HSBC with analyst Sunil Rajgopal saying it is one of the preferred ways to play the sector given its strategic position and financial metrics. The analyst said Verizon has solid scale in wireless, narrow exposure to pay TV, low debt, robust ROIC, and good shareholder returns. 4. CSX (CSX) upgraded to Outperform from Sector Perform at Scotiabank and to Equal Weight from Underweight at Morgan Stanley. 5. Costco (COST) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company is on the "cusp" of an earnings acceleration aided by its credit card deal, and attractive positioning as a low-cost/low-priced operator in a challenging retail environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/16/17
UBSW
02/16/17
NO CHANGE
Target $160
UBSW
Sell
Tesla fundamentals do not support recent run-up in shares, says UBS
UBS analyst Colin Langan said he sees no fundamental reason for the recent run-up in Tesla shares. He said the SolarCity acquisition has added additional risk and complexity to the business, including slowing sales growth, adding an unneeded distraction during a challenging launch period. Langan reiterated his Sell rating and $160 price target on Tesla shares.

TODAY'S FREE FLY STORIES

EEM

MSCI Emerging Markets Index

$46.07

-0.005 (-0.01%)

11:00
12/15/17
12/15
11:00
12/15/17
11:00
Options
90K iShares Emerging Markets Fund Jun 42 puts bought for $1.04 »

90K iShares Emerging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

, PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

SYMC

Symantec

$28.75

0.12 (0.42%)

CHKP

Check Point

$106.30

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

  • 17

    Jan

  • 26

    Feb

ACHN

Achillion

10:51
12/15/17
12/15
10:51
12/15/17
10:51
Recommendations
Achillion analyst commentary  »

Achillion CMO departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGP

Plains GP Holdings

$21.29

0.11 (0.52%)

10:50
12/15/17
12/15
10:50
12/15/17
10:50
Options
Notable option play in Plains GP as a position adjusted »

Notable option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:46
12/15/17
12/15
10:46
12/15/17
10:46
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

FCX

Freeport McMoRan

$16.64

0.45 (2.78%)

10:45
12/15/17
12/15
10:45
12/15/17
10:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/15/17
12/15
10:45
12/15/17
10:45
General news
Chicago Fed's Evans voted against the rate hike »

Chicago Fed's Evans…

TEVA

Teva

$18.42

1.116 (6.45%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Upgrade
Teva rating change  »

Credit Suisse takes Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.49

0.26 (1.35%)

, CS

Credit Suisse

$17.59

0.065 (0.37%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Periodicals
U.S. judge dismisses $3B suit against Deutsche, Credit Suisse, Bloomberg says »

A U.S. judge has thrown…

DB

Deutsche Bank

$19.49

0.26 (1.35%)

CS

Credit Suisse

$17.59

0.065 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

10:40
12/15/17
12/15
10:40
12/15/17
10:40
Hot Stocks
Achillion reports resignation of Chief Medical Officer »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:39
12/15/17
12/15
10:39
12/15/17
10:39
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

TEVA

Teva

$18.39

1.08 (6.24%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXRX

Concordia

$0.86

0.3261 (61.08%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Hot Stocks
Concordia says 'unaware' of material change to account for market activity »

Concordia International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AU

AngloGold

$9.21

0.045 (0.49%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Options
AngloGold put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.26

-0.025 (-0.47%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Hot Stocks
AK Steel says UAW members ratify labor agreement for Dearborn Works »

AK Steel announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:30
12/15/17
12/15
10:30
12/15/17
10:30
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

NDSN

Nordson

$143.86

16.95 (13.36%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Recommendations
Nordson analyst commentary  »

Nordson price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
General news
Treasury Action: Treasuries will remain in a bear-bull tug-o-war into 2018 »

Treasury Action:…

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan household/personal product analyst has analyst/industry conference call »

Beverages, Household…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Cable, Media &…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

DIS

Disney

$110.93

0.36 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan insurance analyst has analyst/industry conference call »

Property & Casualty…

TEVA

Teva

$18.21

0.91 (5.26%)

10:24
12/15/17
12/15
10:24
12/15/17
10:24
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAT

ViaSat

$72.72

0.46 (0.64%)

, EXC

Exelon

$40.80

-0.015 (-0.04%)

10:22
12/15/17
12/15
10:22
12/15/17
10:22
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

VSAT

ViaSat

$72.72

0.46 (0.64%)

EXC

Exelon

$40.80

-0.015 (-0.04%)

ORIG

Ocean Rig UDW

$24.55

-0.17 (-0.69%)

FTR

Frontier Communications

$8.69

-1.51 (-14.80%)

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.